v3.25.2
Commitments and Contingencies (Details)
€ in Millions, $ in Millions
1 Months Ended
May 05, 2025
USD ($)
Apr. 01, 2019
USD ($)
Apr. 30, 2020
USD ($)
Jun. 30, 2025
EUR (€)
NAMENDA XR/Namzaric Qui Tam Litigation        
Long-term Purchase Commitment [Line Items]        
Loss contingency, damages sought, value   $ 2,500.0    
USWM Acquisition        
Long-term Purchase Commitment [Line Items]        
Annual minimum purchase quantity requirement amount | €       € 3.0
Litigation settlement   $ 17.5    
Navitor Pharmaceuticals, Inc.        
Long-term Purchase Commitment [Line Items]        
Collaborative arrangement agreement termination notice period     30 days  
Threshold for development costs payments     $ 50.0  
Collaborative arrangement, payment for one time fee     10.0  
Collaborative arrangement, upfront development costs     25.0  
Collaborative agreement, acquisition-related cost, expense $ 100.0      
Navitor Pharmaceuticals, Inc. | Minimum        
Long-term Purchase Commitment [Line Items]        
Collaborative arrangement, expected development costs     410.0  
Navitor Pharmaceuticals, Inc. | Maximum        
Long-term Purchase Commitment [Line Items]        
Collaborative arrangement, expected development costs     475.0  
Navitor Pharmaceuticals, Inc. | Variable Interest Entity, Not Primary Beneficiary        
Long-term Purchase Commitment [Line Items]        
Investments     $ 15.0  
VIE, qualitative or quantitative information, ownership percentage     13.00%